aimed at convincing regulators to delay approval of potential competitor drugs.
\u201c\ud83d\udea8BIG: Our new report with @IMAKglobal finds Big Pharma\u2019s antitrust violations cost Americans a whopping $40 BILLION on branded pharmaceuticals in 2019.\n\nYou can read the report below, but here\u2019s some additional context and policy solutions.\ud83d\udc47\ud83e\uddf5\nhttps://t.
The groups estimate that Medicare Part D and Medicaid"would have spent approximately 50% less on three of the four major insulin brands in 2019 but for the anticompetitive strategies used by the major insulin manufacturers."in 2020—of engaging in a"sustained, consistent pattern of illegally blocking generic and biosimilar competition in violation of the antitrust laws."
The groups estimate that Part D and Medicaid would have spent 90% less on Bystolic and its generic equivalents in 2019 had Allergan not entered the pay-for-delay agreement, which the FTCThe report also points to a whistlebloweralleging that Janssen Pharmaceuticals—which is owned by Johnson & Johnson—committed patent fraud to prolong its monopoly on Zytiga, a prostate cancer drug.